3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
9
Lymphoma, Non-Hodgkin
6
Lymphoma, Mantle-Cell
5
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma
3
Multiple Myeloma
2
Lymphoma, B-Cell
2
Leukemia
2
Waldenstrom Macroglobulinemia
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Prolymphocytic
1
Leukemia, Hairy Cell
1
Leukemia, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Glioblastoma
1
DLBCL
1
Burkitt Lymphoma
1
Advanced Haematological Malignancies
1
Interventions
Cyclophosphamide
19
fludarabine
18
Tacrolimus
10
Whole-Body Irradiation
9
Mycophenolic Acid
8
venetoclax
7
fludarabine phosphate
7
Sirolimus
7
Azacitidine
7
Mesna
5
Dexamethasone
5
Bortezomib
5
Rituximab
4
Methotrexate
4
Busulfan
4
daratumumab
3
Stem Cell Transplantation
3
Peripheral Blood Stem Cell Transplantation
3
Nivolumab
3
Melphalan
3
Lenalidomide
3
Filgrastim
3
Cytarabine
3
Biopsy
3
Alemtuzumab
3
AP 1903 reagent
3
pomalidomide
2
merphos
2
isatuximab
2
ibrutinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Hematologic Neoplasms
×
acalabrutinib
×
Clear all
NCT05205252
2023-08-15
ARIA
Ipsen
Phase 1/2
Withdrawn